Applies to Employer and ACA Marketplace plans.
Covered with requirementsQualification pathways
You can qualify through any one of these.
Adult obesity
All of:
- Age ≥ 18 years
- BMI ≥ 30 kg/m2
Adult overweight with comorbidity
All of:
- Age ≥ 18 years
- BMI ≥ 27 kg/m2
Plus any one of:
- Hypertension
- T2DM
- dyslipidemia
- OSA
- CVD
- MASH
Asian adult overweight/obesity
All of:
- BMI ≥ 23 kg/m2 (South Asian, Southeast Asian, or East Asian adults)
Documentation to bring
- Baseline BMI documentation (≥ 30 kg/m2 for obesity, or ≥ 27 kg/m2 for overweight)
- Documentation of weight-related comorbidity if BMI 27–29.9 kg/m2
- Age documentation (≥ 18 years)
Approval and renewal
- Renewal: Continuation recommended only for patients achieving at least 5% weight loss and tolerating therapy, assessed after 12 weeks at a therapeutic dose.
- Renewal: At least 12 weeks on therapy before the first renewal.
Not covered when
- Coadministration with other tirzepatide-containing products not recommended
- Coadministration with any GLP-1 receptor agonist not recommended
Policy note: Available as both subcutaneous injection solution vial and Kwikpen formulations. Efficacy assessed after 12 weeks at therapeutic dose; continuation only if ≥ 5% weight loss achieved and therapy tolerated.
Policy effective May 4, 2026 · verified June 2, 2026 · source: Ri Weight Management Prog Sum · View policy document (PDF)